Biotherapeutic Delivery

| December 27, 2017

article image
The idea of combining a drug to a targeting molecule as a ‘Magic Bullet’ was first suggested by the German Physician Paul Erhlich in the early 1900’s.1,2 Antibody Drug Conjugates (ADCs) comprises a monoclonal antibody, linker region, and cytotoxic warhead. The Antibody head binds to specific antigens on the tumor surface. When the ADC is internalized by the tumor cell, the linker is degraded releasing the cytotoxin, leading to cell death.

Spotlight

Medichem, S.A.

Medichem, S.A. is an independently-owned Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) developer and manufacturer. Based in Barcelona (Spain), active in Malta and China, delivering medicines to over 60 markets across the world –including the U.S. and EU- Medichem is a fully-integrated pharmaceutical company with a unique portfolio of non-infringing APIs and FDFs.

OTHER ARTICLES

The Future of Pharma Beyond Blockbusters

Article | March 17, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Comparing HydroxyChloroquine Trials

Article | April 1, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Spotlight

Medichem, S.A.

Medichem, S.A. is an independently-owned Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) developer and manufacturer. Based in Barcelona (Spain), active in Malta and China, delivering medicines to over 60 markets across the world –including the U.S. and EU- Medichem is a fully-integrated pharmaceutical company with a unique portfolio of non-infringing APIs and FDFs.

Events